Abstract
IntroductionTocilizumab is an interleukin-6 (IL-6) receptor blocker which blocks the IL-6 signal transduction pathway reducing inflammation. It is thought to be an effective drug for patients with severe COVID-19 pneumonia....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
